Cologne / Aachen – August 25, 2026 – Vivalyx, an organ vitality tech company developing the next generation of organ preservation solutions, has been formally granted Breakthrough Medical Devices Status by the European Medicines Agency (EMA) under its newly launched program for Vivalyx’s organ preservation solution Omnisol. Omnisol was selected

Marking the company’s transition to clinical stage Rotterdam / Cologne – March 16, 2026 – Organ-vitality-tech company Vivalyx today announced that the first patients have received donated kidneys that were machine-perfused using Vivalyx Omnisol®, the company’s novel organ perfusion preservation solution. This milestone represents Vivalyx’s first-in-human clinical trial experience. It

Aachen, 19th of February 2025 – The organ vitality tech startup Vivalyx has been awarded a €2.5 million grant from the European Innovation Council (EIC) Accelerator, along with a pre-commitment for an additional €6 million in equity investment. This funding will significantly accelerate the market approval of Omnisol – a

Aachen, 30th of April 2024 – Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, announces that it has successfully closed an oversubscribed seed funding round, raising above 5 million EUR. The international investor consortium includes leading European Life Science and Deeptech venture capital firms such as Brightlands Venture

Aachen, 15. Juni 2023. Das Aachener LifeScience-Technologie-Start-up Vivalyx arbeitet an der Zulassung einer neuartigen Flüssigkeit zur Revitalisierung von Spenderorganen. Das Ziel ist es, die Vitalität der Spenderorgane zu steigern und somit die Anzahl der verfügbaren Organe für lebensrettende Transplantationen zu erhöhen. Die Organkonservierungsflüssigkeit soll mit allen gängigen Transportsystemen kompatibel sein: